109 related articles for article (PubMed ID: 9815840)
1. Optimal sampling strategies for bayesian estimation of docetaxel (Taxotere) clearance.
Baille P; Bruno R; Schellens JH; Webster LK; Millward M; Verweij J; Montay G
Clin Cancer Res; 1997 Sep; 3(9):1535-8. PubMed ID: 9815840
[TBL] [Abstract][Full Text] [Related]
2. Analysis of docetaxel pharmacokinetics in humans with the inclusion of later sampling time-points afforded by the use of a sensitive tandem LCMS assay.
Gustafson DL; Long ME; Zirrolli JA; Duncan MW; Holden SN; Pierson AS; Eckhardt SG
Cancer Chemother Pharmacol; 2003 Aug; 52(2):159-66. PubMed ID: 12759775
[TBL] [Abstract][Full Text] [Related]
3. Combination treatment with docetaxel (Taxotere) and platinum compounds for non-small cell lung cancer.
Mattson K; Saarinen A; Jekunen A
Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-5-S14-8. PubMed ID: 9335516
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and metabolism of Taxotere (docetaxel).
Bruno R; Sanderink GJ
Cancer Surv; 1993; 17():305-13. PubMed ID: 7907950
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel (Taxotere) and vinorelbine in the treatment of non-small cell lung cancer.
Georgoulias V; Kourousis C; Androulakis N; Kakolyris S; Papadakis E; Bouros D; Apostolopoulou F; Georgopoulou T; Agelidou M; Souglakos J; Halkiadakis G; Hatzidaki D
Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-9-S14-14. PubMed ID: 9335517
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.
Bruno R; Hille D; Riva A; Vivier N; ten Bokkel Huinnink WW; van Oosterom AT; Kaye SB; Verweij J; Fossella FV; Valero V; Rigas JR; Seidman AD; Chevallier B; Fumoleau P; Burris HA; Ravdin PM; Sheiner LB
J Clin Oncol; 1998 Jan; 16(1):187-96. PubMed ID: 9440742
[TBL] [Abstract][Full Text] [Related]
7. The role of docetaxel (Taxotere) as a single agent or in combination before local treatment of non-small cell lung cancer.
Harper P
Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-30-S14-32. PubMed ID: 9335522
[TBL] [Abstract][Full Text] [Related]
8. The development of docetaxel (Taxotere) in non-small cell lung cancer--docetaxel in new combinations and new schedules: an overview of ongoing and future developments.
Donnellan PP; Crown JP
Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-18-S14-21. PubMed ID: 9335519
[TBL] [Abstract][Full Text] [Related]
9. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial.
Betticher DC; Hsu Schmitz SF; Tötsch M; Hansen E; Joss C; von Briel C; Schmid RA; Pless M; Habicht J; Roth AD; Spiliopoulos A; Stahel R; Weder W; Stupp R; Egli F; Furrer M; Honegger H; Wernli M; Cerny T; Ris HB
J Clin Oncol; 2003 May; 21(9):1752-9. PubMed ID: 12721251
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel (Taxotere) in combination with platinum-based regimens in non-small cell lung cancer: results and future developments.
Belani CP
Semin Oncol; 1999 Jun; 26(3 Suppl 10):15-8. PubMed ID: 10437746
[TBL] [Abstract][Full Text] [Related]
11. Overview of docetaxel (Taxotere)/cisplatin combination in non-small cell lung cancer.
Le Chevalier T; Bérille J; Zalcberg JR; Millward MJ; Monnier A; Douillard JY; McKeage MJ; James R; Soulas F; Loret C; Bougon N; Bizzari JP
Semin Oncol; 1999 Jun; 26(3 Suppl 11):13-8. PubMed ID: 10458205
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion.
Extra JM; Rousseau F; Bruno R; Clavel M; Le Bail N; Marty M
Cancer Res; 1993 Mar; 53(5):1037-42. PubMed ID: 8094996
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer: preliminary results.
Belli L; LeChevalier T; Gottfried M; Adams D; Ruffie P; LeCesne A; Tete L; Pellae-Cosset B
Semin Oncol; 1995 Dec; 22(6 Suppl 15):29-33. PubMed ID: 8643967
[TBL] [Abstract][Full Text] [Related]
14. A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors.
Van Den Neste E; de Valeriola D; Kerger J; Bleiberg H; Kusenda Z; Brassinne C; Bartholomeus S; Selleslags J; Hennebert P; Wythouck H; Cazenave I; Lefresne-Soulas F; Piccart M
Clin Cancer Res; 2000 Jan; 6(1):64-71. PubMed ID: 10656433
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel in lung cancer: 1-hour infusions given alone or in combination chemotherapy.
Hainsworth JD; Greco FA
Semin Oncol; 1995 Dec; 22(6 Suppl 15):45-9. PubMed ID: 8643970
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel (Taxotere) and neoadjuvant chemotherapy for non-small cell lung cancer.
Mattson K
Semin Oncol; 1999 Jun; 26(3 Suppl 10):25-8. PubMed ID: 10437748
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel in the management of advanced non-small cell lung cancer.
Miller VA
Semin Oncol; 1998 Jun; 25(3 Suppl 8):15-9. PubMed ID: 9704671
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel: new indication. First-line treatment of non small-cell lung cancer: no advance.
Prescrire Int; 2005 Feb; 14(75):16-8. PubMed ID: 15751170
[TBL] [Abstract][Full Text] [Related]
19. Summary of phase II data of docetaxel (Taxotere), an active agent in the first- and second-line treatment of advanced non-small cell lung cancer.
Fossella FV; Lee JS; Berille J; Hong WK
Semin Oncol; 1995 Apr; 22(2 Suppl 4):22-9. PubMed ID: 7740327
[TBL] [Abstract][Full Text] [Related]
20. A limited-sampling strategy for estimation of etoposide pharmacokinetics in cancer patients.
Tranchand B; Amsellem C; Chatelut E; Freyer G; Iliadis A; Ligneau B; Trillet-Lenoir V; Canal P; Lochon I; Ardiet CJ
Cancer Chemother Pharmacol; 1999; 43(4):316-22. PubMed ID: 10071983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
